SeraCare Life Sciences launches new products to aid discovery and development of drugs and diagnostics

SeraCare Life Sciences, Inc. (NASDAQ: SRLS) announced today that the Company has added five new, differentiated products to its portfolio to meet the needs of SeraCare’s growing customer base in the life sciences industry.

Susan Vogt, President and Chief Executive Officer stated, “SeraCare ended 2009 with more than 250 new customers across the life sciences industry worldwide and we are pleased to kick off 2010 with the introduction of a variety of products specifically designed to meet the needs of our expanding customer base. The latest additions to our product portfolio continue to set SeraCare apart as a leading provider of high quality products and services that facilitate the discovery, development and manufacturing of drugs and diagnostics.”

SeraCare’s new products include:

• A set of specific controls for infectious disease testing that offer the most comprehensive assay coverage in the industry for the Abbott ARCHITECT testing platform. SeraCare’s new controls set the standard for accuracy, delivering customers the potential for lower cost, more efficient testing and improved error detection in the laboratory.

• ACCURUN^® 1 Series 2700 Multi-Marker Positive Control allows end-users to develop a more efficient quality control program by offering a single product for multiple antigens related to various types of HIV, hepatitis, cytomegalovirus and T-lymphotropic virus.
• ACCURUN^® 106 Series 1000 Positive Control provides positive diagnostic control detection of the HIV type 1 antigen and is critical for monitoring the performance of HIV tests that allow for the early detection of HIV infection.

• Two differentiated, cryopreserved human peripheral blood mononuclear cell (PBMC) products that serve as tools in life science research and drug development. SeraCare’s PBMCs are utilized in immune response monitoring, cytokine production, gene expression analysis, toxicity/immunotoxicity screening, cytotoxicity assays, stimulation and proliferation studies, and biomarker identification and characterization.

• AccuCell^™ Human PBMC-Basic and AccuCell^™ Human PBMC-Characterized products both offer off-the-shelf flexibility. SeraCare’s ability to produce PBMCs in large lots offers customers better assay-to-assay consistency, the option to use lot-specific cells across multiple test sites and the ability to compare assays from multiple time points across multiple preclinical studies or clinical trials.

• A multiplex viral research reagent for use with assays that detect and differentiate influenza viruses. This new product is the only ready to use reagent on the market for assessing and monitoring the performance of influenza assays.

• ACCUTYPE^™ H1N1 is designed to perform on FDA-issued Emergency Use Authorized Medical Devices that detect the H1N1 influenza virus as well as other assays that detect H1N1 viral RNA.